Asuragen of Austin, TX at MEDICA 2018 in Düsseldorf -- MEDICA - World Forum for Medicine

Asuragen

2150 Woodword St., Suite 100, 78744 Austin, TX
USA
Telephone +1 512 6815215
Fax +1 512 6815201
tradeshows@asuragen.com

This company is co-exhibitor of
U.S. Department of Commerce, U.S. Commercial Service

Hall map

MEDICA 2018 hall map (Hall 16): stand C04

Fairground map

MEDICA 2018 fairground map: Hall 16

Our range of products

Product categories

  • 03  Diagnostics
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.03  Polymerase chain reaction (PCR)

Our products

Product category: Polymerase chain reaction (PCR)

AmplideX® mPCR FMR1

  • Eliminates the need for Southern blot analysis
  • Accurately measures the methylation fraction for each FMR1 allele at higher resolution than Southern blot analysis
  • Provides increased sensitivity for the detection of lower abundance mosaic alleles*
  • Includes spike-in digestion and amplification controls to ensure high performance with every sample
  • Designed to complement the AmplideX FMR1 PCR Reagents*
  • Improves turnaround time by fivefold: 10 hours from DNA to data (as compared to 1 week for Southern blot)
Product Description
The AmplideX mPCR FMR1 Kit employs an innovative PCR-only approach for the detection of methylation status in the FMR1 gene. These reagents determine the extent of methylation of each individual allele in both male and female samples, and thus eliminate the need to run tedious and time consuming Southern blots.

More Less

Product category: Polymerase chain reaction (PCR)

QuantideX® qPCR BCR-ABL IS Kit

Assessing complete molecular response requires the highest possible assay sensitivity. The FDA-cleared QuantideX® qPCR BCR-ABL IS Kit takes chronic myeloid leukemia (CML) monitoring to a new level of sensitivity – 0.002% IS (MR4.7). It’s a qPCR-based In Vitro Diagnostic test for the quantitation of BCR-ABL1 and ABL1 transcripts in total RNA from whole blood of diagnosed t(9;22) positive CML patients expressing e13a2 and/or e14a2 fusion transcripts.

Features & Benefits
The QuantideX qPCR BCR-ABL IS Kit’s unprecedented level of sensitivity coupled to a simple-to-run, singlicate test, allows labs to reliably and reproducibly monitor much deeper molecular response.

Reduced Complexity
Ease-of-data analysis and reporting:

  • Direct reporting on the International Scale (IS): No sample exchange or conversion factor calculations required
  • Data analysis software eliminates manual intervention to provide automated calculations and streamlined reporting
Optimized Workflow
Valuable operator hands-on time has been significantly reduced through:

  • Multiplexed design amplifies and detects both fusion and control gene in the same reaction
  • All-inclusive reagents sourced and Quality Controlled together from a single vendor
  • Pre-mixed reagents leading to fewer pipetting steps in the mastermix preparation
Quality Performance
Detecting BCR-ABL Transcripts robustly, reliably with a highly sensitive assay:

  • Limit of Detection (LOD) of MR4.7 (0.002%IS): 95% detection at LOD as determined using human RNA specimens
  • Increased analytical sensitivity without compromising analytical specificity: Non-CML (major) transcripts not detected in assay
  • Armored RNA®-based standards providing true RNA quantification for a quantitative RNA assay
  • Robust performance as indicated by minimum variability of replicate measurements

More Less

About us

Company details

At Asuragen, we believe people deserve better answers. In pursuit of this vision, we have built our culture around providing an exciting and challenging work environment where employees have the freedom to be creative and innovative.

We are a collaborative team where individuals are recognized both for their ability to develop novel solutions to unmet customer needs, and to perform against company goals. We are proud to have a diverse mix of career professionals who design, develop, make and market world-class, innovative and differentiated diagnostic and research products. We are collectively driven to make a difference in how patients are managed today and in the future.

More Less